Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Aug;82(15):5190–5193. doi: 10.1073/pnas.82.15.5190

Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

A de Agostini, M Schapira, Y T Wachtfogel, R W Colman, S Carrel
PMCID: PMC390525  PMID: 2410915

Abstract

The inactivation of human plasma kallikrein (EC 3.4.21.8) by the inhibitor of activated complement component 1 (C1 inhibitor) induces the formation of a 1:1 stoichiometric kallikrein-C1 inhibitor complex and a proteolytically modified form of C1 inhibitor. We have produced a monoclonal antibody that recognizes the kallikrein-C1 inhibitor complex as well as modified C1 inhibitor but fails to react with virgin C1 inhibitor or native plasma kallikrein. This observation constitutes an unequivocal demonstration that the reaction between plasma kallikrein and C1 inhibitor leads to the emergence of an epitope that is undetectable on the parent enzyme and inhibitor molecules.

Full text

PDF
5190

Images in this article

5192Image
on p.5192
5192Image
on p.5192
5192Image
on p.5192

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Accolla R. S., Carrel S., Mach J. P. Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. Proc Natl Acad Sci U S A. 1980 Jan;77(1):563–566. doi: 10.1073/pnas.77.1.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bouma B. N., Miles L. A., Beretta G., Griffin J. H. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry. 1980 Mar 18;19(6):1151–1160. doi: 10.1021/bi00547a018. [DOI] [PubMed] [Google Scholar]
  3. Carrel S., Heumann D., Sekaly R. P., Zaech P., Buchegger F., Girardet C. Characterization of a monoclonal antibody (A12) that defines a human acute lymphoblastic leukemia-associated differentiation antigen. Hybridoma. 1983;2(2):149–160. doi: 10.1089/hyb.1983.2.149. [DOI] [PubMed] [Google Scholar]
  4. Collen D. Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors. Thromb Res. 1974 Dec;5(6):777–779. doi: 10.1016/0049-3848(74)90121-2. [DOI] [PubMed] [Google Scholar]
  5. Colman R. W. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest. 1984 May;73(5):1249–1253. doi: 10.1172/JCI111326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colman R. W., Wachtfogel Y. T., Kucich U., Weinbaum G., Hahn S., Pixley R. A., Scott C. F., de Agostini A., Burger D., Schapira M. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood. 1985 Feb;65(2):311–318. [PubMed] [Google Scholar]
  7. Fuchs H. E., Shifman M. A., Pizzo S. V. In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin III-thrombin and alpha 2-macroglobulin-methylamine. Biochim Biophys Acta. 1982 May 27;716(2):151–157. doi: 10.1016/0304-4165(82)90263-x. [DOI] [PubMed] [Google Scholar]
  8. Galfrè G., Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981;73(Pt B):3–46. doi: 10.1016/0076-6879(81)73054-4. [DOI] [PubMed] [Google Scholar]
  9. Gigli I., Mason J. W., Colman R. W., Austen K. F. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol. 1970 Mar;104(3):574–581. [PubMed] [Google Scholar]
  10. Gonias S. L., Fuchs H. E., Pizzo S. V. A unique pathway for the plasma elimination of alpha 2-antiplasmin-protease complexes in mice. Thromb Haemost. 1982 Oct 29;48(2):208–210. [PubMed] [Google Scholar]
  11. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  12. Lau H. K., Rosenberg R. D. The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. J Biol Chem. 1980 Jun 25;255(12):5885–5893. [PubMed] [Google Scholar]
  13. Lewin M. F., Kaplan A. P., Harpel P. C. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. J Biol Chem. 1983 May 25;258(10):6415–6421. [PubMed] [Google Scholar]
  14. Mandle R., Jr, Kaplan A. P. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. J Biol Chem. 1977 Sep 10;252(17):6097–6104. [PubMed] [Google Scholar]
  15. McDuffie F. C., Peterson J. M., Clark G., Mann K. G. Antigenic changes produced by complex formation between thrombin and antithrombin-III. J Immunol. 1981 Jul;127(1):239–244. [PubMed] [Google Scholar]
  16. Merril C. R., Switzer R. C., Van Keuren M. L. Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and a highly sensitive silver stain. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4335–4339. doi: 10.1073/pnas.76.9.4335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Reboul A., Arlaud G. J., Sim R. B., Colomb M. G. A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s. FEBS Lett. 1977 Jul 1;79(1):45–50. doi: 10.1016/0014-5793(77)80347-5. [DOI] [PubMed] [Google Scholar]
  18. Schapira M., Scott C. F., Colman R. W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982 Feb;69(2):462–468. doi: 10.1172/JCI110470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schapira M., Scott C. F., Colman R. W. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry. 1981 May 12;20(10):2738–2743. doi: 10.1021/bi00513a006. [DOI] [PubMed] [Google Scholar]
  20. Scott C. F., Liu C. Y., Colman R. W. Human plasma prekallikrein: a rapid high-yield method for purification. Eur J Biochem. 1979 Oct;100(1):77–83. doi: 10.1111/j.1432-1033.1979.tb02035.x. [DOI] [PubMed] [Google Scholar]
  21. Shifman M. A., Pizzo S. V. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem. 1982 Mar 25;257(6):3243–3248. [PubMed] [Google Scholar]
  22. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  24. Wallgren P., Nordling K., Björk I. Immunological evidence for a proteolytic cleavage at the active site of antithrombin in the mechanism of inhibition of coagulation serine proteases. Eur J Biochem. 1981 Jun 1;116(3):493–496. doi: 10.1111/j.1432-1033.1981.tb05363.x. [DOI] [PubMed] [Google Scholar]
  25. de Agostini A., Lijnen H. R., Pixley R. A., Colman R. W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest. 1984 Jun;73(6):1542–1549. doi: 10.1172/JCI111360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. van der Graaf F., Koedam J. A., Bouma B. N. Inactivation of kallikrein in human plasma. J Clin Invest. 1983 Jan;71(1):149–158. doi: 10.1172/JCI110743. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES